Analysis of clinical-pharmacological approaches to the rational use of drugs in chronic heart failure

Chronic heart failure (CHF) is a complex clinical syndrome with high morbidity and mortality. Rational pharmaceutical management is fundamental in improving symptoms, enhancing quality of life, and reducing hospitalizations and mortality. This article reviews current clinical-pharmacological strategies for CHF treatment, emphasizing evidence-based drug classes, therapeutic mechanisms, and rational prescription practices. Key drug categories include angiotensin-converting enzyme inhibitors (ACEIs), beta-adrenergic blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and diuretics. Additionally, new agents and optimization strategies are discussed. Flowcharts and diagrams illustrate treatment pathways and decision points. The analysis supports a patient-centered, risk-benefit approach to drug selection based on comorbidities, renal function, and individual tolerability.